Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors

BACKGROUND: Acquired drug resistance is the greatest obstacle to the successful treatment of multiple myeloma (MM). Despite recent advanced treatment options such as liposomal formulations, proteasome inhibitors, immunomodulatory drugs, myeloma-targeted antibodies, and histone deacetylase inhibitors...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:J Hematol Oncol
Main Authors: Turner, Joel G., Dawson, Jana L., Grant, Steven, Shain, Kenneth H., Dalton, William S., Dai, Yun, Meads, Mark, Baz, Rachid, Kauffman, Michael, Shacham, Sharon, Sullivan, Daniel M.
Format: Artigo
Sprog:Inglês
Udgivet: BioMed Central 2016
Fag:
Research
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4997728/
https://ncbi.nlm.nih.gov/pubmed/27557643
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-016-0304-z
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker